5 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 2 | Terminated 2 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cystoscopic Ablation Via RF Energy Clinical Trial Amphora OAB Device - Overactive Bladder | Phase 1 / Phase 2 | Terminated | Amphora Medical, Inc. | 63 | 2015-02-01 | 2019-05-07 |
| Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients BTX mixed with TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Terminated | UroGen Pharma Ltd. | 3 | 2014-07-01 | 2016-03-01 |
| An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics High resolution urodynamic assessment, Conventional urodynamic assessment - Healthy Subjects, Overactive Bladder | Phase 1 | Terminated | Astellas Pharma Europe Ltd. | 6 | 2012-03-01 | 2014-10-15 |
| A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) Vibegron, Tolterodine ER, Placebo (vibegron) - Overactive Bladder, Overactive Urinary Bladder | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 4 | 2012-02-27 | 2018-12-24 |
| Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity hMaxi-K, Placebo - Overactive Bladder | Phase 1 | Terminated | Urovant Sciences GmbH | 21 | 2007-04-01 | 2019-06-28 |
Urinary Bladder, Overactive (5)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Lower Urinary Tract Symptoms (5) · Male Urogenital Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Urological Manifestations (5)
Cephalexin (1) · Chemoprevention (1) · Levofloxacin (1) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (1) · Tolterodine Tartrate (1)
Amphora Medical, Inc. (1) · Astellas Pharma Europe Ltd. (1) · Merck Sharp & Dohme LLC (1) · UroGen Pharma Ltd. (1) · Urovant Sciences GmbH (1)
Belgium (1) · Canada (1) · Israel (1) · Netherlands (1) · United States (1)
Ami Sidi, Prof MD (1) · Roger Demochowski, MD (1)